| Completed | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder Bipolar I Disorder, Bipolar II Disorder, Schizophrenia | Phase 2 | 2025-06-19 |
| Completed | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Di Bipolar Disorder, Schizophrenia, Agitation,Psychomotor | Phase 4 | 2023-10-02 |
| Terminated | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) Agitation, Dementia | Phase 3 | 2022-12-14 |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder | Phase 3 | 2022-11-21 |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) Agitation, Dementia | Phase 3 | 2022-04-27 |
| Terminated | An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia Agitation, Dementia | Phase 2 | 2022-02-08 |
| Recruiting | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Di Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic | Phase 1 | 2021-08-27 |
| Withdrawn | Study of BXCL501 In Agitation Associated With Delirium in ICU Patients Agitation, Delirium | Phase 2 | 2021-02-23 |
| Completed | Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Opioid Withdrawal | Phase 1 / Phase 2 | 2020-06-09 |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder | Phase 3 | 2020-02-24 |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia Agitation, Schizophrenia, Schizo Affective Disorder | Phase 3 | 2020-01-24 |
| Completed | Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia Agitation,Psychomotor, Dementia | Phase 1 / Phase 2 | 2019-12-27 |
| Withdrawn | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic | EARLY_Phase 1 | 2019-10-15 |
| Completed | Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia Agitation, Schizophrenia | Phase 1 | 2019-05-22 |
| Completed | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer o Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma | Phase 1 / Phase 2 | 2019-02-12 |